Importantly, in line with the increased E-cadherin mRNA levels, Tocilizumab-treated H6c7-kras cells that had been exposed to M1 macrophages and hyperglycemia showed a reduced migratory ability in the scratch assay compared with the respective cells treated with Rituximab (Figure 7E). This evidence concerns the gene CDH1 and Hyperglycemia.